G. W. Sledge

发表

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.

Yu Shyr, William J. Gradishar, G. Sledge, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.